Canine Cushing's Case Files: The ins and outs of detection and treatment—The economics of managing hyperadrenocorticism in dogs (Sponsored by Dechra Veterinary Products)
The impact of managing a chronic disease
Consider the impact that management of just one common chronic disease can have on your practice's bottom line. How many canine patients with hyperadrenocorticism did you identify and treat in the last 12 months? What's the incremental gross and net income from treating and monitoring a dog with hyperadrenocorticism in the 12 months after detection, and how much impact does your pricing have on a client's ability and willingness to treat the disease?Cushing's disease is a chronic illness that is not cured, but rather managed throughout a pet's life. What's the annual financial impact of managing patients with Cushing's syndrome on your practice? What's the long-term benefit to your practice of skillfully managing a dog with Cushing's disease and having the owners happy that their dog's clinical signs have resolved?
A year in the life of Riley
Consider a case example such as Riley,* a 12-year-old spayed female beagle that weighs 27 lb (12.3 kg). Her owners have historically taken good care of riley and followed their longtime veterinarian's advice. Riley presented with common clinical signs of canine hyperadrenocorticism — polyuria and polydipsia, polyphagia, alopecia, and a pendulous abdomen.
Diagnosing canine hyperadrenocorticism can be fairly straightforward based on a dog's history, clinical signs, and results of readily available diagnostic tests (see the previous Canine Cushing's Case Files in this series, 'Dali,' 'Princess,' and 'Mitch'). Examination and screening for other concurrent disease processes is also indicated.
Once the diagnosis is confirmed, VETORYL® CAPSULES (trilostane), the only FDA-approved drug indicated for medical treatment of both pituitary- and adrenal-dependent hyperadrenocorticism in dogs, can be prescribed.